The DOI matches its Crossref record, with a small difference in title or year; 15 of the 15 references it cites were found in a registry or an index.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain. METHODS: We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to-event analysis. RESULTS: Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients (19.5%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.92; P<0.001). Worsening heart failure occurred in 368 patients (11.8%) in the dapagliflozin group and in 455 patients (14.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.69 to 0.91); cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05). Total events and symptom burden were lower in the dapagliflozin group than in the placebo group. Results were similar among patients with a left ventricular ejection fraction of 60% or more and those with a left ventricular ejection fraction of less than 60%, and results were similar in prespecified subgroups, including patients with or without diabetes. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk of DKA is increased in persons using SGLT2is, especially in those being treated with insulin (especially if there has been a recent reduction in their insulin dose) and/or those with acute illnesses and prolonged fasting.1049,1050”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1049]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) and DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), SGLT2 inhibition reduced the risk of cardiovascular death and worsening HF events by 18% to 21%4,5 and improved KCCQ-CSS by 1.5 to 2.3 points”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (302).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (290).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [290]
In the citing paper
“Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalization by 22% in those with an LVEF below or equal to the median of 57%.534”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“DELIVER recruited 6263 patients with heart failure with mildly reduced or preserved (>40%) ejection fraction including 3109 patients without diabetes.”
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
In the citing paper
“Approximately 44% of patients randomized to either dapaglifl ozin or placebo had type 2 diabetes, and results were consistent regardless of the presence of type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
In the citing paper
“The primary outcome of a composite of worsening heart failure, de fi ned as hospitalization or urgent visit for heart failure, or cardiovascular death was reduced by 18% in patients treated with dapagli fl ozin compared with placebo (HR 0.82 [95% CI 0.73 -0.92]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationCategorical Data Analysis Using the SAS System
Ziegel, E. R., Stokes, M., Davis, C., & Koch, G. (1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 2,034
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationSolomon, S. D., Claggett, B. L., Lewis, E. F., Desai, A. S., Anand, I. S., Sweitzer, N. K., O’Meara, E., Shah, S. J., McKinlay, S. M., Fleg, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 538
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,002
Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?
Kondo, T., Henderson, A. D., Docherty, K. F., Jhund, P. S., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.033 · Cited by 20
Self-citationCarrizales‐Sepúlveda, E. F., Ordaz‐Farías, A., Vargas-Mendoza, J. A., Vera‐Pineda, R., & Flores‐Ramírez, R. (2024) · Cardiac failure review · doi:10.15420/cfr.2023.20 · Cited by 18
Christodorescu, R., Geavlete, O. D., Ferrini, M., Kümler, T., Toutoutzas, K., Bayés‐Genís, A., Seferovic, P. M., Metra, M., Chioncel, O., Rosano, G. M. C., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3444 · Cited by 18
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18
Simela, C., Walker, J. M., Ghosh, A. K., & Chen, D. H. (2025) · Cardio-Oncology · doi:10.1186/s40959-024-00284-4 · Cited by 21
RADAKRISHNAN, A., AGRAWAL, S., SINGH, N., Barbieri, A., Shaw, L. J., Gulati, M., & Lala, A. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.01.008 · Cited by 19
Karakasis, P., Theofilis, P., Patoulias, D., Vlachakis, P. K., Pamporis, K., Sagris, Μ., Ktenopoulos, N., Kassimis, G., Antoniadis, A. P., & Fragakis, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104494 · Cited by 18
Albertini, M., Waldmann, V., David, P., Barat, A., Legendre, A., Chaussade, A., Iserin, L., & Ladouceur, M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040302 · Cited by 18
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 24
Metra, M., Tomasoni, D., Adamo, M., Amir, O., Anker, S. D., Bayés‐Genís, A., Böehm, M., Butler, J., Chioncel, O. D., Filippatos, G. S., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15408 · Cited by 23
Yue, T., Zheng, D., He, J., Xiong, S., Xu, J., & Hou, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1676988 · Cited by 18
The Role of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Tzoumas, A., Tapp, D. N., Crousillat, D. R., Honigberg, M. C., Lozano, P. F. R., Aggarwal, N. R., Ebong, I., Briller, J. E., de Oliveira, G. M., Harrington, C. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102345 · Cited by 23
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
Vaduganathan, M., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M., Lam, C. S. P., Martínez, F. A., Shah, S. J., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.745 · Cited by 18
Self-citationPatoulias, D., Fragakis, N., & Rizzo, M. (2022) · Life · doi:10.3390/life12122062 · Cited by 19
Pistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 19
Clephas, P. R. D., Aydin, D., Radhoe, S. P., & Brugts, J. J. (2023) · Sensors · doi:10.3390/s23031364 · Cited by 18
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Chan, J. C. H., & Chan, M. C. Y. (2023) · Medicina · doi:10.3390/medicina59020388 · Cited by 25
Ducharme, A., Zieroth, S. R., Ahooja, V., Anderson, K., Andrade, J. G., Boivin‐Proulx, L., Ezekowitz, J. A., Howlett, J. G., Lepage, S., Leong, D., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.04.022 · Cited by 19
Self-citationObesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
Stencel, J. D., Alai, H. R., Dhore-Patil, A., Urina‐Jassir, D., & Jemtel, T. H. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093341 · Cited by 20
New Therapeutics for Heart Failure: Focusing on cGMP Signaling
Mangmool, S., Duangrat, R., Parichatikanond, W., & Kurose, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612866 · Cited by 19
Fu, Q., Zhou, L., Fan, Y., Liu, F., Fan, Y., Zhang, X., Li, W., & Cheng, L. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03591-3 · Cited by 18
Atrial Shunt Therapy for Heart Failure: An Update
Jagadeesan, V. S., Gray, W. A., & Shah, S. J. (2023) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2023.101203 · Cited by 18
Self-citationHabel, N., Infeld, M. M., Bernknopf, J., Meyer, M., & Lustgarten, D. L. (2023) · Heart Rhythm O2 · doi:10.1016/j.hroo.2023.12.001 · Cited by 19
Oka, K., Masuda, T., Ohara, K., Miura, M., Morinari, M., Misawa, K., Miyazawa, Y., Akimoto, T., Shimada, K., & Nagata, D. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1287066 · Cited by 18
Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review
Lava, S. A. G., Laurence, C., Deo, A. D., Sekarski, N., Burch, M., & Pasqua, O. E. D. (2024) · Pediatric Drugs · doi:10.1007/s40272-024-00623-z · Cited by 18
Treatment of type 2 diabetes mellitus in the elderly – Special considerations
Gadó, K., Tabák, Á. G., Vingender, I., Domján, G., & Dörnyei, G. (2024) · Physiology International · doi:10.1556/2060.2024.00317 · Cited by 24
Lin, Y., Tsai, W., Chiu, C., Chi, N.-Y., Liu, Y., Huang, T., Wu, W.-T., Lin, T., Lai, W.-T., Sheu, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158541 · Cited by 18
Tang, H., Zhang, B., Lu, Y., Donahoo, W. T., Ospina, N. S., Kotecha, P., Lu, Y., Tong, J., Smith, S. M., Rosenberg, E. I., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16147 · Cited by 18
Byer, S. H., Sivamurugan, A., Grewal, U. S., Fradley, M. G., & Dominic, P. S. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.01.012 · Cited by 18
Effects of SGLT2 inhibitors on ion channels in heart failure: focus on the endothelium
Wang, M., Preckel, B., Zuurbier, C. J., & Weber, N. C. (2025) · Basic Research in Cardiology · doi:10.1007/s00395-025-01115-y · Cited by 20
Rodrigues, M. M., & Falcão, L. M. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133182 · Cited by 18
Clinical utility of the left atrial strain analysis
Inoue, K., & Obokata, M. (2025) · Journal of Echocardiography · doi:10.1007/s12574-025-00695-x · Cited by 17
SGLT2 inhibitors and acute kidney injury
Nakao, Y., Mori, M., Mori, Y., & Bonventre, J. V. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf132 · Cited by 18
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101069 · Cited by 20
Gibb, A., LaPenna, K. B., Gaspar, R. B., Latchman, N. R., Tan, Y. F., Choya-Foces, C., Doiron, J. E., Li, Z., Xia, H., Lazaropoulos, M. P., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101334 · Cited by 20
Shokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17
van Weperen, V. Y. H., & Vaseghi, M. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-01000-6 · Cited by 25
The Cardiovascular Effects of SGLT2 Inhibitors, RAS Inhibitors, and ARN Inhibitors in Heart Failure
Ji, P., Zhang, Z., Yan, Q., Cao, H., Zhao, Y., Yang, B., & Li, J. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14298 · Cited by 17
Zhang, N., Harsch, B. A., Zhang, M. J., Gyberg, D. J., Stevens, J. A., Wagner, B. M., Mendelson, J. B., Patterson, M. T., Orchard, D. A., Healy, C. L., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100374 · Cited by 19
Lawson, C. A., Tay, W. T., Bernhardt, L., Richards, M., Zaccardi, F., Tromp, J., Teng, T. K., Hung, C., Chandramouli, C., Wander, G. S., et al. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.03.005 · Cited by 17
Self-citationTang, Y., & Sang, H. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14426 · Cited by 17
Bapir, R., Bhatti, K. H., Eliwa, A., García‐Perdomo, H. A., Gherabi, N., Hennessey, D. B., Magri, V., Mourmouris, P., Ouattara, A., Perletti, G., et al. (2023) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2023.11509 · Cited by 18
Raven, L. M., Muir, C. A., & Greenfield, J. R. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.52067 · Cited by 17
Wahlberg, K. J., Infeld, M. M., Plante, T. B., Novelli, A., Habel, N., Burkhoff, D., Barrett, T. C., Lustgarten, D. L., & Meyer, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.032873 · Cited by 17
Fudim, M., Litwin, S. E., Borlaug, B. A., Mohan, R. C., Price, M. J., Fail, P. S., Zirakashvili, T., Shaburishvili, T., Goyal, P., Hummel, S. L., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.12.010 · Cited by 17
Self-citationNoh, H., Joo, S. Y., Kim, C. H., Choi, S.-W., Lee, C. H., & Hwang, J. K. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02389-3 · Cited by 17
Zhou, R., Xia, Y., Li, Z., Wu, L., Shi, Y. P., Ling, Z., & Zhang, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-55996-5 · Cited by 18
Schupp, T., Bertsch, T., Reinhardt, M., Abel, N., Schmitt, A., Lau, F., Abumayyaleh, M., Akin, M., Weiß, C., Weidner, K., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae121 · Cited by 18
Hiraiwa, H., Okumura, T., & Murohara, T. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00641-9 · Cited by 19
Asakura, M., Masuda, T., Oka, K., Ohara, K., Miura, M., Morinari, M., Misawa, K., Miyazawa, Y., Akimoto, T., Shimada, K., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14111194 · Cited by 17
Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds
Benedikt, M., Oulhaj, A., Rohrer, U., Manninger, M., Tripolt, N. J., Pferschy, P. N., Aziz, F., Wallner, M., Kolesnik, E., Gwechenberger, M., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400147 · Cited by 17
Jeon, J. Y., & Kim, D. J. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0317 · Cited by 19
Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
Cersosimo, A., Drera, A., Adamo, M., Metra, M., & Vizzardi, E. (2024) · Kidney and Dialysis · doi:10.3390/kidneydial4040016 · Cited by 21
SAKAMOTO, D., Sotomi, Y., Matsuoka, Y., Nakatani, D., Okada, K., Sunaga, A., Kida, H., Sato, T., Kitamura, T., SEO, M., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.440 · Cited by 17
Harada, M., Motoike, Y., Nomura, Y., Nishimura, A., Koshikawa, M., Watanabe, E., Ozaki, Y., & Izawa, H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132954 · Cited by 17
Lin, Y., Wu, J., Lee, M.-C., Su, C.-Y., Toh, H. S., Chang, W., Chen, S.-Y., Kuo, F., Tang, H., & Liao, C. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae093 · Cited by 17
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 18
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Butt, J. H., Docherty, K. F., Claggett, B. L., Desai, A. S., Fang, J. C.-T., Petersson, M., Langkilde, A. M., de Boer, R. A., Honorio, J. W. C., Hernandez, A. F., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.11.014 · Cited by 19
Self-citationKhoo, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00079-x · Cited by 17
Guidelines for treating heart failure
Kittleson, M. M. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.10.002 · Cited by 18
Trask-Marino, A. L., Marino, B., Lancefield, T. F., See, E. J., May, C. N., Booth, L. C., Raman, J., & Lankadeva, Y. R. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2024 · Cited by 19
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Thompson, S., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030624 · Cited by 19
The interplay between heart failure and chronic kidney disease
Lala, A., Levin, A., & Khunti, K. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16371 · Cited by 16
Kaul, S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.036 · Cited by 16
Vaduganathan, M., Claggett, B. L., Chatur, S., Desai, A. S., Jhund, P. S., Vardeny, O., Merkely, B. P., Martínez, F. A., Colet, J. C., Saraiva, J. F. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04037-3 · Cited by 18
Self-citationShlyakhto, E. V., Belenkov, Y. N., Boytsov, S. A., Вадимовна, В. С., Galyavich, A. S., Глезер, М. Г., Звартау, Н. Э., Kobalava, Z. D., Lopatin, Y. M., VIu, M., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6516 · Cited by 16
Self-citationNeumiller, J. J., Lienhard, F. J., Alicic, R. Z., & Tuttle, K. R. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.106 · Cited by 17
A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome
Sano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065983 · Cited by 16
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Jerkins, T. W., McGill, J. B., & Bell, D. S. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15062 · Cited by 19
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
Kondo, T., Wang, X., Yang, M., Jhund, P. S., Claggett, B. L., Vaduganathan, M., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., Martínez, F. A., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.056 · Cited by 17
Self-citationA big STEP for treatment of heart failure with preserved ejection fraction
Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Petrie, M. C., Shah, S. J., Dhingra, N. K., & Kosiborod, M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.08.003 · Cited by 16
Self-citationBalligand, J., Brito, D. A., Brosteanu, O., Casadei, B., Depoix, C. L., Edelmann, F., Ferreira, V. M., Filippatos, G. S., Gerber, B. L., Gruson, D., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.3003 · Cited by 18
Bhatt, A. S., Kosiborod, M., Claggett, B. L., Miao, Z. M., Vaduganathan, M., Lam, C. S. P., Hernandez, A. F., Martínez, F. A., Inzucchi, S. E., Shah, S. J., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3043 · Cited by 16
Self-citationBakbak, E., Verma, S., Krishnaraj, A., Quan, A., Wang, C., Pan, Y., Puar, P., Mason, T., Verma, R., Terenzi, D. C., et al. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00141.2023 · Cited by 16
Self-citationThe Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF
Triposkiadis, F. K., Briasoulis, Α., Sarafidis, P. A., Magouliotis, D. E., Athanasiou, T., PARASKEVAIDIS, I. A., Skoularigis, J. S., & Xanthopoulos, A. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206486 · Cited by 18
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials
Kondo, T., Gasparyan, S. B., Jhund, P. S., Bengtsson, O., Claggett, B. L., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M., Køber, L., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300042 · Cited by 16
Self-citationde la Espriella, R., Wahlberg, K. J., Infeld, M. M., Palau, P., Núñez, E., Sanchís, J. M., Meyer, M., & Núñez, J. E. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3107 · Cited by 16
Cersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 17
Kittipibul, V., Vaduganathan, M., Ikeaba, U., Chiswell, K., Butler, J., DeVore, A. D., Heidenreich, P. A., Huang, J., Kittleson, M. M., Maddox, K. E. J., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.003 · Cited by 17
Self-citationYang, M., Kondo, T., Talebi, A., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3263 · Cited by 19
Self-citationYang, M., Kondo, T., Jhund, P. S., Alcocer-Gamba, M. A., Borleffs, C. J. W., Chiang, C., Colet, J. C., Desai, A. S., Dobreanu, D., Dróżdż, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3352 · Cited by 16
Self-citationUsing multiple primary endpoints in clinical trials with a focus on heart failure
Anker, S. D., Butler, J., Talha, K. M., & Friede, T. (2024) · Global Cardiology · doi:10.4081/cardio.2024.33 · Cited by 16
Germán, J. B., Cortés, M., López, C. R., Otero, J. M. R., Chapel, J. A. E., Becerra, A. J. B., Roca, L. N., Urquía, M. T., Lázaro, A. M. P., & Tuñón, J. (2024) · Biomedicines · doi:10.3390/biomedicines12071507 · Cited by 16
Sato, R., Koziolek, M. J., & von Haehling, S. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.10.024 · Cited by 16
Kattih, B., Fischer, A., Muhly-Reinholz, M., Tombor, L. S., Nicin, L., Cremer, S., Zeiher, A. M., John, D., Abplanalp, W. T., & Dimmeler, S. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.11.004 · Cited by 16
Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
Chinese Society of Cardiology, C. M. A., Chinese College of Cardiovascular Physician, Chinese Heart Failure Association of Chinese Medical Doctor Association, & Editorial Board of Chinese Journal of Cardiology (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000146 · Cited by 17
Defining the need for cardiovascular event definitions
Bhatty, A., Wilkinson, C., Sydes, M. R., & Gale, C. P. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae008 · Cited by 16
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 18
Ricken, K. W. L. M., Lenselink, C., Venema, C. S., van der Horst, I. C. C., van der Horst, I. C. C., Pundziūtė, G., Voors, A. A., & Lipšic, E. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132931 · Cited by 15
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3440 · Cited by 19
Self-citationHu, L., Liu, Y., Liu, Y., Xu, Z., Pan, P., & Zeng, L. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04649-0 · Cited by 17
Dapagliflozin Effect On Functional Mitral Regurgitation and Myocardial Remodelling: The DEFORM Trial
Huang, Z., Fan, R., Zhang, S., Zhong, J., Huang, Y., Xie, P., Yin, S., Ye, X., Xu, X., Huang, R., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15296 · Cited by 15
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Lam, C. S. P., BRINKER, M. D., Schloemer, P., Viswanathan, P., Lage, A. Z., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3649 · Cited by 15
Self-citationMirzai, S., Sandesara, U. B., Haykowsky, M. J., Brubaker, P. H., Kitzman, D. W., & Peters, A. E. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10526-x · Cited by 22
Okuno, T., Kagami, K., Harada, T., Hoshiga, M., Ishii, H., & Obokata, M. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0214 · Cited by 18
Acute heart failure in non-cardiac surgery
Gualandro, D. M., Masip, J., Halvorsen, S., Price, S., Rosselló, X., Chioncel, O. D., Peacock, W. F., Miró, Ò., de Oliveira, M. T., Mebazaa, A., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf559 · Cited by 15
One Syndrome, Many Faces: A Unified Perspective on Heart Failure Phenotypes
PARASKEVAIDIS, I. A., Tsougos, E., & Kourek, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188960 · Cited by 16
Vlasopoulou, K., Synetos, A. G., Ktenopoulos, N., Katsaros, O., Koliastasis, L., Apostolos, A., Drakopoulou, M. I., Toutouzas, K. P., & Tsioufis, K. P. (2025) · Medical Sciences · doi:10.3390/medsci13030204 · Cited by 19
Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
Pruett, J. E., Lirette, S. T., Romero, D. G., & Cardozo, L. L. Y. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac191 · Cited by 16
Girerd, N., & Zannad, F. M. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13620 · Cited by 17
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., Fang, J. C., Alcocer-Gamba, M. A., Al Habeeb, W., Han, Y., Cabrera Honorio, J. W., Janssens, S. P., Katova, T., Kitakaze, M., Merkely, B., O’Meara, E., Saraiva, J. F. K., Tereshchenko, S. N., Thierer, J., Vaduganathan, M., Vardeny, O., Verma, S., Pham, V. N., Wilderäng, U., Zaozerska, N., Bachus, E., Lindholm, D., Petersson, M., & Langkilde, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., B.C., A.S.D., M.V.); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M., P.S.J.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (R.A.B., C.S.P.L.), and Haga Teaching Hospital, the Hague (C.J.W.B.) — both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (A.F.H.); Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (M.N.K.); National Heart Center Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); National University of Cordoba, Cordoba (F.M.), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norbert...
- Northwestern University (US)
- Semmelweis University (HU)
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Claggett, Brian
- de Boer, Rudolf A.
- DeMets, David
- Hernandez, Adrian F.
- Inzucchi, Silvio E.
- Kosiborod, Mikhail N.
- Lam, Carolyn S.P.
- Shah, Sanjiv J.
- Desai, Akshay S.
- Jhund, Pardeep S.
- Chiang, Chern-En
- Dobreanu, Dan
- Fang, James C.
- Alcocer-Gamba, Marco Antonio
- Han, Yaling
- Janssens, Stefan P.
- Kitakaze, Masafumi
- Merkely, Béla
- O’Meara, Eileen
- Tereshchenko, Sergey N.
- Thierer, Jorge
- Vaduganathan, Muthiah
- Vardeny, Orly
- Verma, Subodh
- Pham, Vinh Nguyen
- Wilderäng, Ulrica
- Bachus, Erasmus
- Lindholm, Daniel
- Petersson, Magnus
- Langkilde, Anna Maria
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-22
- Volume
- 387
- Issue
- 12
- Pages
- 1089-1098
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4293354639
- Cited by
- 2,884
- References
- 15
- Citations by year
- 2026: 635 · 2025: 716 · 2024: 714 · 2023: 673 · 2022: 139
- FWCI
- 390.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (KU Leuven) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, SGLT2 inhibitors, heart failure, preserved ejection fraction, mildly reduced ejection fraction, heart failure hospitalization, cardiovascular mortality, left ventricular ejection fraction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Humans, Stroke Volume, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
